Equities

Dyadic International Inc

DYAI:NAQ

Dyadic International Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)1.84
  • Today's Change0.171 / 10.22%
  • Shares traded191.28k
  • 1 Year change-11.96%
  • Beta0.8285
Data delayed at least 15 minutes, as of May 22 2024 21:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Dyadic International, Inc. is a biotechnology company focused on the large-scale manufacture of proteins for use in human and animal vaccines and therapeutics and for use in non-pharmaceutical applications including food, nutrition, and wellness. The Company's gene expression and protein production platforms are based on the highly productive and scalable fungus Thermothelomyces heterothallica (formerly Myceliophthora thermophila). Its lead technology, C1-cell protein production platform, is based on an industrially proven microorganism (named C1), which is used to speed development and improve performance of biologic vaccines and drugs at flexible commercial scales for the human and animal health markets. The Company has also developed the Dapibus filamentous fungal based microbial protein production platform to enable the rapid development and large-scale manufacture of low-cost proteins, metabolites, and other biologic products for use in non-pharmaceutical applications.

  • Revenue in USD (TTM)2.26m
  • Net income in USD-7.85m
  • Incorporated2002
  • Employees7.00
  • Location
    Dyadic International Inc1044 NORTH U.S. HIGHWAY ONE, SUITE 201JUPITER 33477United StatesUSA
  • Phone+1 (561) 743-8333
  • Fax+1 (561) 743-8343
  • Websitehttps://dyadic.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Gain Therapeutics Inc0.00-21.14m45.13m29.00--5.22-----1.53-1.530.000.4790.00----0.00-117.80---164.29---------13,827.07----0.0555---60.6221.77-26.59--13.96--
Movano Inc0.00-29.28m45.30m30.00--7.46-----0.6463-0.64630.000.06180.00----0.00-258.41-151.50-496.87-188.58--------1.26--0.014------3.45--4.24--
Aadi Bioscience Inc23.84m-68.83m45.43m75.00--0.5022--1.91-2.55-2.550.88483.680.16920.60214.54267,865.20-48.86-50.25-56.39-56.1587.70---288.72-473.974.86--0.00--60.063.85-8.68--153.54--
Immuneering Corp0.00-54.18m45.67m65.00--0.5801-----1.86-1.860.002.650.00----0.00-55.37---58.58--------------0.00---100.00---5.86------
NextCure Inc0.00-63.73m46.72m82.00--0.4705-----2.29-2.290.003.550.00----0.00-45.05-22.59-47.72-23.54-------964.96----0.00------16.07---23.17--
Arca Biopharma Inc0.00-6.00m47.00m4.00--1.34-----0.4155-0.41550.002.420.00----0.00-15.24-27.78-15.81-29.38------------0.00------46.21------
Journey Medical Corp80.00m-4.16m47.22m58.00--5.19--0.5903-0.3095-0.30954.130.64980.9852.274.281,379,276.00-5.12---17.85--66.22---5.20--0.93570.40490.5773--7.48--87.00------
Clene Inc.620.00k-48.81m47.52m82.00--11.14--76.65-0.4764-0.47640.00530.03320.01462.119.767,560.98-114.91-39.43-233.02-47.3278.71---7,873.23-5,261.201.22-32.640.8641--38.27---65.47------
Cidara Therapeutics Inc46.38m-36.47m48.45m69.00------1.04-8.07-8.0710.26-3.900.6899--2.80672,144.90-54.24-65.23-218.59-154.3776.93---78.63-100.610.6047-------0.8425--31.72--23.33--
Dyadic International Inc2.26m-7.85m48.81m7.00--10.79--21.64-0.2724-0.27240.07830.15470.1769--4.51322,197.20-61.58-36.82-73.50-39.8538.2422.47-348.00-410.16----0.5634---1.0717.4830.20------
Aligos Therapeutics Inc13.79m-99.59m49.87m67.00--0.841--3.62-1.51-1.510.17960.75920.1105----208,969.70-79.78-51.20-98.27-59.73-----722.06-1,399.21----0.0037--11.66--8.71---62.36--
Carmell Corp0.00-18.29m49.93m9.00---------1.58-1.490.00-0.07190.00----0.00-428.46------58.60-------------------75.70------
Modular Medical Inc0.00-16.76m51.44m37.00--9.20-----0.9653-0.96530.000.18050.00----0.00-224.40-168.16-262.22-209.51------------0.00------25.51--154.53--
Data as of May 22 2024. Currency figures normalised to Dyadic International Inc's reporting currency: US Dollar USD

Institutional shareholders

14.56%Per cent of shares held by top holders
HolderShares% Held
Bandera Partners LLCas of 31 Mar 20241.57m5.41%
Chapin Davis, Inc. (Investment Management)as of 31 Mar 2024826.30k2.85%
The Vanguard Group, Inc.as of 31 Mar 2024796.65k2.75%
Northeast Financial Consultants, Inc.as of 31 Mar 2024250.00k0.86%
BlackRock Fund Advisorsas of 31 Mar 2024244.10k0.84%
Geode Capital Management LLCas of 31 Mar 2024224.39k0.77%
Sage Mountain Advisors LLCas of 31 Mar 2024106.56k0.37%
Northern Trust Investments, Inc.(Investment Management)as of 31 Mar 202477.60k0.27%
HighTower Advisors LLCas of 31 Mar 202477.32k0.27%
Perkins Capital Management, Inc.as of 31 Mar 202447.85k0.17%
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.